These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22847190)

  • 1. Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro.
    Lü JM; Yan S; Jamaluddin S; Weakley SM; Liang Z; Siwak EB; Yao Q; Chen C
    Med Sci Monit; 2012 Aug; 18(8):BR293-298. PubMed ID: 22847190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
    Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
    Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.
    Doherty KM; Nakka P; King BM; Rhee SY; Holmes SP; Shafer RW; Radhakrishnan ML
    BMC Bioinformatics; 2011 Dec; 12():477. PubMed ID: 22172090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.
    Weber J; Mesters JR; Lepsík M; Prejdová J; Svec M; Sponarová J; Mlcochová P; Skalická K; Strísovský K; Uhlíková T; Soucek M; Machala L; Stanková M; Vondrásek J; Klimkait T; Kraeusslich HG; Hilgenfeld R; Konvalinka J
    J Mol Biol; 2002 Dec; 324(4):739-54. PubMed ID: 12460574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Protease Inhibitors Containing C-5-Modified
    Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART.
    Gehringer H; Bogner JR; Goebel FD; Nitschko H; von der Helm K
    J Clin Virol; 2000 Aug; 17(2):137-41. PubMed ID: 10942094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-2 Protease resistance defined in yeast cells.
    M'Barek NB; Audoly G; Raoult D; Gluschankof P
    Retrovirology; 2006 Sep; 3():58. PubMed ID: 16956392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
    Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV protease activity from rosa family plant extracts and rosamultin from Rosa rugosa.
    Park JC; Kim SC; Choi MR; Song SH; Yoo EJ; Kim SH; Miyashiro H; Hattori M
    J Med Food; 2005; 8(1):107-9. PubMed ID: 15857219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the potency of HIV-1 protease drugs to combat resistance.
    Hou T; McLaughlin WA; Wang W
    Proteins; 2008 May; 71(3):1163-74. PubMed ID: 18004760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease inhibitor resistance update: where are we now?
    Kim R; Baxter JD
    AIDS Patient Care STDS; 2008 Apr; 22(4):267-77. PubMed ID: 18422460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ginkgolic acids induce neuronal death and activate protein phosphatase type-2C.
    Ahlemeyer B; Selke D; Schaper C; Klumpp S; Krieglstein J
    Eur J Pharmacol; 2001 Oct; 430(1):1-7. PubMed ID: 11698056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
    Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.